Sawai Group Holdings
Basic Information
- Stock Code
- 4887
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Osaka Prefecture
- Establishment Year
- April 2021
- Listing Year
- April 2021
- Official Website
- https://www.sawaigroup.holdings
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Ship HD, Fuso Pharmaceutical, Towa Pharmaceutical, Fuji Pharmaceutical Industries
Overview
Sawai Pharmaceutical is a major generic drug company established in 1948, based in Japan with operations in the United States, leading the industry in manufacturing and selling generic pharmaceuticals.
Current Situation
In the fiscal year ended March 2024, Sawai Pharmaceutical achieved net sales of 176.7 billion yen, operating income of 23.5 billion yen, and net income of 15.9 billion yen, maintaining a stable financial foundation. It holds a top-class domestic market share in its mainstay generic drug sector and has expanded its business in the US market through the acquisition of Upsher-Smith Laboratories. With the transition to a holding company structure in 2021, it has strengthened group management and advanced the sophistication of R&D and quality management systems. In 2023, a quality testing irregularity was uncovered, but it established a new Quality Control Division and is focusing on compliance enhancement. Moving forward, it aims to further expand generic drugs and strengthen competitiveness in the US market, improve quality, and restore customer trust. Addressing patent infringement lawsuits and international regulatory compliance are also key challenges. Sustainable medical provision and enhanced legal compliance are mid- to long-term management priorities.
Trivia
Interesting Facts
- Long-established company originating from Sawai Pharmacy founded in 1929
- Top-class market share in Japan's generic pharmaceutical industry
- Strengthened overseas expansion by acquiring US Upsher-Smith Laboratories
- Received numerous generic pharmaceutical awards
- Packaging designs won multiple international awards
- Large CM character images displayed on head office building along Shin-Midosuji
- Implemented thorough quality control review and system strengthening even after irregularity exposure
- Also manufactures injection syringes and other injectables
- Operates multiple large-scale factories in Kyushu, Kanto, Mita, etc.
- Product expansion in diverse fields like antiallergy agents and sleep inducers
- Represented by long-term Sawai family management
- Solid growth company listed on the First Section of the Tokyo Stock Exchange
- Nationwide network of regionally rooted branches and sales offices
- Aggressively promoting production switch between medical and OTC drugs for growth
- Recently advancing automation of manufacturing management using IT and AI
Hidden Connections
- Sawai Group Holdings maintains partnership and technology exchanges with multiple major Japanese pharmaceutical companies
- Successfully expanded overseas markets by leveraging international network through US subsidiary acquisition
- While upholding family management tradition, recently transitioned to professional management system
- Contributes to activation of Japan's generic pharmaceutical market, aligned with government policies
- Holds multiple pharmaceutical manufacturing technology patents, maintaining technological superiority in the industry
- Its response to the quality irregularity incident influenced industry-wide compliance strengthening standards
- Actively provides education and information to regional healthcare professionals, promoting industry exchanges
- Contributes to healthcare cost containment through generic pharmaceutical dissemination
Future Outlook
Growth Drivers
- Expansion of domestic generic pharmaceutical demand
- Increasing medical needs due to aging society
- Business growth through M&A in the US market
- Competitiveness enhancement via new technology development and formulation innovation
- Customer trust recovery through quality management strengthening
- Regulatory easing and government generic drug promotion policies
- Production efficiency improvement through IT adoption
- Utilization of global networks
- Enhanced management flexibility through holding company structure
- Development of diverse sales channels
Strategic Goals
- Expansion of domestic and international generic pharmaceutical market share
- Over 30% revenue ratio from global operations centered on the US
- Achieve world-class quality management system
- Enrich product lineup through new formulation technologies
- Establish production system meeting sustainability standards
- Continuous promotion of legal compliance and ethical management
- Maximize operational efficiency through digital technology utilization
- Strengthen collaboration with local communities and expand social responsibility
- Foster diverse talent and create better working environments
- Expand R&D investments for sustainable growth
Business Segments
Pharmaceutical Manufacturing Outsourcing (CMO)
- Overview
- Provides pharmaceutical manufacturing outsourcing (CMO) services to pharmaceutical companies with high-quality control.
- Competitiveness
- Integration of formulation research and mass production technology
- Customers
-
- Domestic and international pharmaceutical companies
- Generic drug manufacturers
- Biopharmaceutical developers
- Medical institutions
- Products
-
- Pharmaceutical manufacturing consignment
- Packaging & supply management
- Quality management services
Pharmaceutical Logistics & Supply Management
- Overview
- Deploys logistics services supporting efficient pharmaceutical distribution and inventory management.
- Competitiveness
- Extensive logistics network and IT integration
- Customers
-
- Wholesalers
- Pharmacy chains
- Hospitals & clinics
- Retail stores
- Products
-
- Inventory management systems
- Distribution networks
R&D Support
- Overview
- Provides broad technical support for formulation development and clinical trials.
- Competitiveness
- High technological capabilities and track record
- Customers
-
- Pharmaceutical companies
- University research institutions
- Medical institutions
- Products
-
- Formulation technology provision
- Clinical trial support
Overseas Business Expansion Support
- Overview
- Supports overseas expansion primarily in the US, aiding local regulatory clearance and quality management.
- Competitiveness
- Market expansion through overseas M&A
- Customers
-
- Overseas pharmaceutical companies
- Generic companies
- Importers/exporters
- Products
-
- Overseas regulatory compliance support
- Local production management
Competitive Advantage
Strengths
- Top domestic generic pharmaceutical market share
- Business base expansion in the US market
- Advanced formulation technology
- Management strengthening through holding company structure
- Rich product lineup
- Immediate quality control improvement system
- Stable financial foundation
- Strong domestic sales network
- Diverse sales channels
Competitive Advantages
- Enhanced international competitiveness through Upsher-Smith acquisition in the US
- Possesses advanced formulation research center for rapid generic product development
- Stable supply via multi-factory production system
- Strengthening legal compliance and quality assurance systems
- Responds to customer diversity with broad product portfolio
- Executes efficient group-wide management under holding company structure
- Rich award history and reliability in generic pharmaceuticals
- Strong legal support system for domestic and international regulatory compliance
- Regular information provision activities to medical institutions
Threats
- Risk of reputational damage from pharmaceutical quality irregularities
- Compensation burdens from patent infringement lawsuits
- Intensifying drug price decline pressure in domestic market
- Price competition from increasing new entrants
- Regulatory tightening and intensifying competition in US market
- Rising raw material prices and supply instability
- Increasing costs for aging manufacturing equipment
- Impact from global policy changes on healthcare systems
- Competitive disadvantage from delays in formulation development innovations
Innovations
2023: Quality Control Division established to strengthen quality management system
- Overview
- Established organization to unify quality management across all six factories in response to quality irregularity issue.
- Impact
- Promotes trust recovery and product quality stabilization
2022: US Upsher-Smith integration completed
- Overview
- Completed business integration post-acquisition of US generic drug company, achieving share expansion in Europe and America.
- Impact
- Significant increase in overseas sales ratio
2021: Transition to holding company structure
- Overview
- Shifted to holdings structure to strengthen group management and nurture new businesses.
- Impact
- Improved management efficiency and promotion of strategic investments
2020: Cetirizine Hydrochloride OD Tablets antiallergy agent wins top award
- Overview
- Recognized as an outstanding generic product by the pharmaceutical association.
- Impact
- Enhanced product brand value
2024: Enhanced development of new formulation technologies
- Overview
- Expansion of research facilities at the formulation center for new technology development.
- Impact
- Accelerated new product development and quality improvement
2023: Advanced production management through IT utilization
- Overview
- Introduced AI and IoT into factory production processes to promote efficiency and defect rate reduction.
- Impact
- Manufacturing cost reduction and quality stabilization
2022: Introduction of low-environmental-impact packaging materials
- Overview
- Sequentially adopting new packaging technology aimed at plastic reduction.
- Impact
- Reduced environmental impact and improved corporate image
2021: Cilostazol OD Tablets antiplatelet agent award
- Overview
- Received formulation development technology award from the Japan Society of Hospital Pharmacists.
- Impact
- Elevated technological evaluation domestically and internationally
2023: Introduction of automated quality testing system
- Overview
- Utilizes robot technology in testing processes to prevent human error.
- Impact
- Improved testing accuracy and efficient scandal prevention
2024: Generic pharmaceutical development acceleration program
- Overview
- Implemented R&D process overhaul to shorten development periods.
- Impact
- Succeeded in shortening time-to-market
Sustainability
- Environmental management system certification at all factories
- Reduction in plastic use and promotion of recycling
- Promotion of regional medical support programs
- Improvement in working environment and enhanced employee health management
- Continuous quality assurance improvement activities
- Strengthened waste reduction initiatives
- Energy optimization toward a decarbonized society
- Thorough legal compliance and ethical management
- Implementation of environmental education and awareness activities
- Sustainable development through collaboration with local communities